Table 1: Characteristics of 800 patients with RA.

Characteristic

 Age (years)51.92 (12.19)a
 Age at onset (years)39.58 (12.35)a
 RA duration (years) 10 (14)b
 Educational level (years)11 (9)b
 Body mass index24 (5.8)b
 DAS283.63 (2.12)b
 HAQ 1.05 (1.31)b

Sociodemographic n/N (%)

 Female650/800 (81.3)
 Low educational level264/692 (38.2)
 Low socioeconomic status234/780 (30.0)
 Current smoking85/768 (11.1)
 Household duties254/684 (37.1)

Clinical aspects

 Type 2 diabetes32/737 (4.3)
 Dyslipidemia184/752 (24.5)
 Hypertension208/752 (27.7)
 Thrombosis39/738 (5.3)
 Cardiovascular disease173/781 (22.2)
 Body mass index > 25394/681 (57.9)
 Abdominal obesity460/683 (67.4)
 Aspirin use105/653 (16.1)
 Abnormal cholesterol179/333 (53.8)

RA characteristics

 Disease duration > 10 years393/703 (55.9)
 Erosions349/451 (77.4)
 EAMs with CVD 402/793 (50.7)
 Rheumatoid factor+573/717 (79.9)
 Anti CCP+312/384 (81.3)
 Methotrexate702/794 (88.4)
 DMARD (any)783/794 (98.6)
 Antimalarials633/793 (79.8)
 Steroids705/793 (88.9)
 Biological Agents276/794 (34.8)

Autoimmunity

 Autoimmune thyroid disease78/800 (9.8)
 Systemic lupus erythematosus11/709 (1.6)
 Sjögren’s syndrome24/800 (3.0)
 Polyautoimmunity 113/800 (14.1)
 Polyautoimmunityc35/800 (4.8)
 MAS17/714 (2.4)
 Familial autoimmunity FDR104/800 (13.0)
 ANAs+310/448 (69.2)
 Anti Ro+43/287 (15.0)
 Anti La+20/285 (7.0)
 TPOAb+51/135 (37.8)
 TgAb+26/125 (20.8)

ANAs: antinuclear antibodies; CCP: cyclic citrullinated peptide; CRP: C-reactive protein; CVD: cardiovascular disease; DAS28: disease activity score; DMARD: disease modifying antirheumatic drugs; EAM: extra-articular manifestations; ESR: erythrocyte sedimentation rate; FDR: first degree relatives; HAQ: health assessment questionnaire; MAS: multiple autoimmune syndrome; RA: rheumatoid arthritis; TgAb: anti-thyroglobulin; TPOAb: anti-thyroperoxidase enzyme.
a Mean (standard deviation).
b Median (interquartile range).
c Without taking AITD into account.